Is NSIP Contagious or Cancer? What Patients Should Know
At a Glance
NSIP is not cancer and cannot spread between people. It is inflammation and scarring in the lung’s supporting tissue, not an infection, although medicines that suppress the immune system can raise infection risk. New or rapidly worsening breathing symptoms need prompt medical evaluation.
The short answer is no. Non-specific interstitial pneumonia (NSIP) itself is not cancer, and it is not a contagious infection you can catch from or pass on to someone else [1] [2].
What Does “Pneumonia” Mean Here?
Because the word “pneumonia” is in the name, many people understandably assume it is an infection. In everyday language, “pneumonia” usually means an infection inside the air sacs of the lungs. However, in NSIP, the term simply describes a pattern of non-infectious inflammation and fibrosis (scarring) in the interstitium—the supportive connective tissue that surrounds the air sacs [1] [2].
NSIP can occur without a known cause (idiopathic) or be associated with autoimmune conditions, where your immune system attacks your own body [3]. While NSIP itself is not cancer, it is possible for a person to have both conditions independently, and your doctor will continue to monitor your lung health [1].
The HIV Connection
You may read that NSIP is sometimes associated with HIV [4]. While it is true that NSIP has been reported in some people living with HIV, this does not mean NSIP is a virus. The exact reason for this connection is uncertain, but it is believed to be related to the immune system’s altered state [4].
People with compromised immune systems are also susceptible to opportunistic infections—infections that take advantage of a weakened immune system. A prime example is Pneumocystis jirovecii pneumonia (PJP), a fungal infection [5]. PJP is a true infection, whereas NSIP is not.
Infection Risk During Treatment
While you cannot pass NSIP to anyone, the treatments for it can make you more vulnerable to catching infections. Medications like corticosteroids, mycophenolate, or rituximab may be used in selected patients to suppress the immune system and reduce lung inflammation [6]. This immunosuppression can increase your risk of bacterial, viral, or fungal infections [6] [7].
Infections Can Mimic Worsening NSIP
If you develop a respiratory infection while on immunosuppressants, the symptoms can look and feel remarkably similar to a sudden worsening (acute exacerbation) of your NSIP [8] [9].
On a CT scan, both an infection and an NSIP flare can cause similar or overlapping findings, such as ground-glass opacities (cloudy spots on the imaging) [10] [11]. Because imaging alone cannot reliably distinguish between an infection and an NSIP flare, your medical team will likely need to evaluate the clinical context and perform additional testing—such as blood cultures, respiratory viral testing, or sometimes a bronchoscopy—to see what is happening [9].
Clinicians will also evaluate for other urgent causes of sudden breathlessness, such as a blood clot or heart issues [8]. Doctors may start you on antimicrobial treatments while waiting for test results, while carefully managing your immunosuppressant doses. Do not start, stop, or change your medication doses without your doctor’s guidance [12].
When to Seek Medical Care
An acute exacerbation of NSIP, an infection, or other complications can all cause sudden breathing difficulties. You should follow an individualized action plan from your doctor outlining your specific oxygen thresholds and when to call.
Tip: Always keep an up-to-date medication list (including the dates of treatments like rituximab) and inform urgent care staff immediately that you have interstitial lung disease and are taking immune-suppressing medications.
Go to the emergency room or call emergency services if you experience:
- Severe breathlessness at rest or an inability to speak in full sentences [13]
- A sudden drop in oxygen levels below your doctor’s prescribed target, or blue lips [14] [13]
- Chest pain, confusion, or fainting [13]
- A rapid deterioration in your breathing over hours or days [15] [8]
Contact your clinic the same day for assessment if you notice:
Common questions in this guide
Can I catch NSIP from another person?
Is NSIP a form of lung cancer?
Why is pneumonia part of the name if NSIP is not an infection?
Can NSIP be linked to autoimmune disease or HIV?
Do medicines for NSIP make infections more likely?
How can doctors tell an infection from an NSIP flare?
When should I get emergency help for NSIP symptoms?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on Non-specific interstitial pneumonia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Could my current symptoms be an infection rather than my NSIP getting worse?
- 2.Are there specific seasonal or pneumococcal vaccines I should receive, and is the timing affected by my immunosuppressive therapy?
- 3.At what specific oxygen saturation level or breathing rate should I go to the emergency room instead of calling the clinic?
- 4.Based on my treatment plan, do I need to be on a preventive medicine to protect against opportunistic infections like Pneumocystis?
References
References (17)
- 1
Ultrasound in Rheumatologic Interstitial Lung Disease: A Case Report of Nonspecific Interstitial Pneumonia in Rheumatoid Arthritis.
Laria A, Lurati A, Scarpellini M
Case reports in rheumatology 2015; (2015()):107275 doi:10.1155/2015/107275.
PMID: 26240772 - 2
Idiopathic non-specific interstitial pneumonia.
Belloli EA, Beckford R, Hadley R, Flaherty KR
Respirology (Carlton, Vic.) 2016; (21(2)):259-68 doi:10.1111/resp.12674.
PMID: 26564810 - 3
Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management.
Yoo H, Hino T, Hwang J, et al.
European journal of radiology open 2022; (9()):100419 doi:10.1016/j.ejro.2022.100419.
PMID: 35445144 - 4
Noninfectious and Nonneoplastic Conditions Associated with Human Immunodeficiency Virus Infection.
George MP, Singh V, Gladwin MT
Seminars in respiratory and critical care medicine 2016; (37(2)):289-302 doi:10.1055/s-0036-1572560.
PMID: 26974305 - 5
Pneumocystis Pneumonia Presenting With Peripheral Predominant Consolidation and Traction Bronchiectasis.
Fujishima N, Hioki Y, Yokoyama A, et al.
Cureus 2024; (16(6)):e63257 doi:10.7759/cureus.63257.
PMID: 39070459 - 6
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.
Mankikian J, Caille A, Reynaud-Gaubert M, et al.
The European respiratory journal 2023; (61(6)) doi:10.1183/13993003.02071-2022.
PMID: 37230499 - 7
A case of invasive pulmonary aspergillosis during treatment for acute exacerbation of interstitial lung disease.
Ugajin M, Kani H
Infectious disease reports 2018; (10(3)):7785 doi:10.4081/idr.2018.7785.
PMID: 30662692 - 8
Acute Exacerbation of Interstitial Lung Disease: Early Diagnosis and Treatment.
León-Román F, Martínez-Besteiro E, Iturbe D, et al.
Medicina (Kaunas, Lithuania) 2025; (61(12)) doi:10.3390/medicina61122097.
PMID: 41470099 - 9
Procalcitonin in acute exacerbation of interstitial lung disease: A systematic review of current evidence.
Srivali N, De Giacomi F
Heart & lung : the journal of critical care 2025; (73()):221-227 doi:10.1016/j.hrtlng.2025.05.014.
PMID: 40482597 - 10
Bispecific T-Cell Engagers-Induced Interstitial Lung Disease: Two Case Reports Confirmed by Transbronchial Lung Cryobiopsy.
Morviducci M, Maraz F, Ravaglia C, et al.
Respiration; international review of thoracic diseases 2025; (104(11)):880-886 doi:10.1159/000547111.
PMID: 40570828 - 11
The Significance of Subpleural Sparing in CT Chest: A State-of-the-Art Review.
Chong WH, Saha BK, Austin A, Chopra A
The American journal of the medical sciences 2021; (361(4)):427-435 doi:10.1016/j.amjms.2021.01.008.
PMID: 33487401 - 12
Prognostic comparison of acute exacerbations across idiopathic interstitial pneumonia subtypes: A nationwide observational study.
Awano N, Aso S, Izumo T, et al.
Respiratory investigation 2025; (63(6)):1229-1234 doi:10.1016/j.resinv.2025.10.001.
PMID: 41056590 - 13
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.
Conte P, Ascierto PA, Patelli G, et al.
ESMO open 2022; (7(2)):100404 doi:10.1016/j.esmoop.2022.100404.
PMID: 35219244 - 14
The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K, Handa T, Nakashima R, et al.
Respiratory medicine 2017; (127()):57-64 doi:10.1016/j.rmed.2017.04.007.
PMID: 28461123 - 15
Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study.
Abe M, Tsushima K, Matsumura T, et al.
Drug design, development and therapy 2015; (9()):5755-62 doi:10.2147/DDDT.S90739.
PMID: 26566367 - 16
Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD).
Yamakawa H, Ogura T, Kameda H, et al.
Journal of clinical medicine 2021; (10(17)) doi:10.3390/jcm10173806.
PMID: 34501253 - 17
Acute Exacerbation in Interstitial Lung Disease.
Leuschner G, Behr J
Frontiers in medicine 2017; (4()):176 doi:10.3389/fmed.2017.00176.
PMID: 29109947
This page is for informational purposes only and does not constitute medical advice. It explains why NSIP is not contagious or cancer, but new or worsening breathing symptoms should be assessed by your healthcare team.